Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.
Ontology highlight
ABSTRACT: There is substantial evidence that cerebrospinal fluid (CSF) levels of both Abeta42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both Abeta and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF Abeta42 levels were used to stratify the sample into those with and wi
SUBMITTER: Kauwe JS
PROVIDER: S-EPMC2430357 | biostudies-literature | 2008 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA